<p>Syndax Pharmaceuticals, Inc.（納斯達克代碼：SNDX - 獲取免費報告）的股票在週二交易中下跌了 7.4%，原因是其財報令人失望。該股最低交易價格為 14.23 美元，最後交易價格為 14.34 美元。在午盤交易中，共交易了 1,069,083 股，較平均每日交易量 2,257,449 股下降了 53%。該股此前收盤價為 15.48 美元。</p>
<p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>該公司報告的每股收益為（$1.10），低於市場共識預期的（$0.31），差距為（$0.79）。該公司本季度的收入為 768 萬美元，而分析師預期為 8632 萬美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商最近對 SNDX 發表了看法。StockNews.com 在 11 月 23 日的報告中將 Syndax Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。花旗集團在 11 月 19 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 37.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。加拿大豐業銀行在 1 月 8 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 18.00 美元下調至 16.00 美元，並對該股給予 “行業表現” 評級。摩根大通在 11 月 21 日的報告中將 Syndax Pharmaceuticals 的目標價從 33.00 美元上調至 38.00 美元，並給予該股 “增持” 評級。最後，高盛在 11 月 7 日的報告中將 Syndax Pharmaceuticals 的目標價從 30.00 美元上調至 33.00 美元，並給予該公司 “買入” 評級。一位分析師對該股給予了 “賣出” 評級，一位給予了 “持有” 評級，九位給予了 “買入” 評級。根據 MarketBeat 的數據，Syndax Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 36.20 美元。</p>
<p><strong>獲取我們關於 SNDX 的最新研究報告</strong></p>
<h2>內部人士下注</h2>
<p>在其他新聞中，首席執行官 Michael A. Metzger 在 2 月 10 日的交易中出售了 13,288 股該股票。該股以平均價格 15.50 美元出售，總價值為 205,964.00 美元。出售後，首席執行官現在直接持有 300,121 股公司股票，價值約為 4,651,875.50 美元。這代表着他們持股比例下降了 4.24%。該交易已在向 SEC 提交的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 Neil Gallagher 在 2 月 10 日的交易中出售了 4,618 股公司的股票。該股以平均價格 15.50 美元出售，總交易額為 71,579.00 美元。交易完成後，該內部人士現在持有 85,095 股公司股票，價值約為 1,318,972.50 美元。該交易使其持股比例下降了 5.15%。該出售的披露信息可以在這裏找到。在上個季度，內部人士共出售了 21,683 股公司股票，價值 336,087 美元。公司內部人士持有公司股票的 4.10%。</p>
<h2>機構資金流入和流出</h2>
<p>多家對沖基金和其他機構投資者最近調整了對該公司的持股。道富集團在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 4.1%。道富集團目前持有 3,770,826 股公司股票，價值 72,588,000 美元，在此期間又增持了 148,491 股。Soleus Capital Management L.P.在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P.目前持有 2,492,000 股公司股票，價值 32,944,000 美元，在此期間又購買了 1,401,016 股。Assenagon Asset Management S.A.在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 343.0%。Assenagon Asset Management S.A.目前持有 2,064,456 股公司股票，價值 27,292,000 美元，在上個季度又購買了 1,598,428 股。Geode Capital Management LLC 在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 3.5%。Geode Capital Management LLC 目前持有 1,977,082 股公司股票，價值 38,066,000 美元，在此期間又購買了 66,459 股。最後，富蘭克林資源公司在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 13.4%。富蘭克林資源公司目前持有 1,763,277 股公司股票，價值 34,948,000 美元，在上個季度又購買了 208,043 股。</p>
<h2>Syndax Pharmaceuticals 股票表現</h2>
<p>該公司的市值為 12.3 億美元，市盈率為-3.97，貝塔係數為 0.90。該公司的 50 日移動平均線為 14.23 美元，200 日移動平均線為 16.75 美元。</p>
<h2>關於 Syndax Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Syndax Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的、針對 menin-MLL 結合相互作用的小分子抑制劑，用於治療 KMT2A 重排的急性白血病和實體腫瘤；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
<h2>特色故事</h2>
<ul>
<li>五隻我們更看好的股票超過 Syndax Pharmaceuticals</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>特斯拉股票：尋找底部可能需要時間</li>
<li>投資石油股票的方式和原因</li>
<li>Duolingo：這隻被打壓的股票即將反彈 38%</li>
<li>股息貴族的最佳名單：通過貴族指數積累財富</li>
<li>Zoom 股票：在 Skype 退出後引領視頻市場</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
<p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Syndax Pharmaceuticals 並不在名單上。</p>
<p>雖然 Syndax Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

Syndax制藥

<p>Syndax Pharmaceuticals（納斯達克代碼：SNDX）股價下跌 7.4%，至 14.34 美元，因財報令人失望，每股收益（EPS）低於預期 0.79 美元，報告收入為 768 萬美元，遠低於 8632 萬美元的預期。分析師的評級不一，其中一位為賣出，另一位為持有，九位為買入。首席執行官 Michael A. Metzger 和內部人士 Neil Gallagher 最近出售了股份，減少了他們的持股比例。機構投資者增加了持股，其中 State Street Corp 和 Soleus Capital Management 是 notable investors。該公司的市值為 12.3 億美元，專注於癌症治療</p>

<p>Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) dropped 7.4% during trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.23 and last traded at $14.34. 1,069,083 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 2,257,449 shares. The stock had previously closed at $15.48.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc.（納斯達克代碼：SNDX - 獲取免費報告）的股票在週二交易中下跌了 7.4%，原因是其財報令人失望。該股最低交易價格為 14.23 美元，最後交易價格為 14.34 美元。在午盤交易中，共交易了 1,069,083 股，較平均每日交易量 2,257,449 股下降了 53%。該股此前收盤價為 15.48 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million.</p>
<div class="lb-trans"><p>該公司報告的每股收益為（$1.10），低於市場共識預期的（$0.31），差距為（$0.79）。該公司本季度的收入為 768 萬美元，而分析師預期為 8632 萬美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages have recently weighed in on SNDX. StockNews.com lowered shares of Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 23rd. Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 19th. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase &amp; Co. raised their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group upped their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $36.20.</p>
<div class="lb-trans"><p>多家券商最近對 SNDX 發表了看法。StockNews.com 在 11 月 23 日的報告中將 Syndax Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。花旗集團在 11 月 19 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 37.00 美元上調至 45.00 美元，並給予該公司 “買入” 評級。加拿大豐業銀行在 1 月 8 日的研究報告中將 Syndax Pharmaceuticals 的目標價從 18.00 美元下調至 16.00 美元，並對該股給予 “行業表現” 評級。摩根大通在 11 月 21 日的報告中將 Syndax Pharmaceuticals 的目標價從 33.00 美元上調至 38.00 美元，並給予該股 “增持” 評級。最後，高盛在 11 月 7 日的報告中將 Syndax Pharmaceuticals 的目標價從 30.00 美元上調至 33.00 美元，並給予該公司 “買入” 評級。一位分析師對該股給予了 “賣出” 評級，一位給予了 “持有” 評級，九位給予了 “買入” 評級。根據 MarketBeat 的數據，Syndax Pharmaceuticals 目前的共識評級為 “適度買入”，共識目標價為 36.20 美元。</p>
</div><p><strong>Get Our Latest Research Report on SNDX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 SNDX 的最新研究報告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 Michael A. Metzger 在 2 月 10 日的交易中出售了 13,288 股該股票。該股以平均價格 15.50 美元出售，總價值為 205,964.00 美元。出售後，首席執行官現在直接持有 300,121 股公司股票，價值約為 4,651,875.50 美元。這代表着他們持股比例下降了 4.24%。該交易已在向 SEC 提交的法律文件中披露，您可以通過此鏈接訪問。此外，內部人士 Neil Gallagher 在 2 月 10 日的交易中出售了 4,618 股公司的股票。該股以平均價格 15.50 美元出售，總交易額為 71,579.00 美元。交易完成後，該內部人士現在持有 85,095 股公司股票，價值約為 1,318,972.50 美元。該交易使其持股比例下降了 5.15%。該出售的披露信息可以在這裏找到。在上個季度，內部人士共出售了 21,683 股公司股票，價值 336,087 美元。公司內部人士持有公司股票的 4.10%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp raised its position in Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Soleus Capital Management L.P. grew its holdings in Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after purchasing an additional 1,401,016 shares during the period. Assenagon Asset Management S.A. increased its position in Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after buying an additional 66,459 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock valued at $34,948,000 after buying an additional 208,043 shares in the last quarter.</p>
<div class="lb-trans"><p>多家對沖基金和其他機構投資者最近調整了對該公司的持股。道富集團在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 4.1%。道富集團目前持有 3,770,826 股公司股票，價值 72,588,000 美元，在此期間又增持了 148,491 股。Soleus Capital Management L.P.在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P.目前持有 2,492,000 股公司股票，價值 32,944,000 美元，在此期間又購買了 1,401,016 股。Assenagon Asset Management S.A.在第四季度將其在 Syndax Pharmaceuticals 的持股增加了 343.0%。Assenagon Asset Management S.A.目前持有 2,064,456 股公司股票，價值 27,292,000 美元，在上個季度又購買了 1,598,428 股。Geode Capital Management LLC 在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 3.5%。Geode Capital Management LLC 目前持有 1,977,082 股公司股票，價值 38,066,000 美元，在此期間又購買了 66,459 股。最後，富蘭克林資源公司在第三季度將其在 Syndax Pharmaceuticals 的持股增加了 13.4%。富蘭克林資源公司目前持有 1,763,277 股公司股票，價值 34,948,000 美元，在上個季度又購買了 208,043 股。</p>
</div><h2>Syndax Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股票表現</h2>
</div><p>The company has a market capitalization of $1.23 billion, a PE ratio of -3.97 and a beta of 0.90. The company's fifty day moving average is $14.23 and its 200-day moving average is $16.75.</p>
<div class="lb-trans"><p>該公司的市值為 12.3 億美元，市盈率為-3.97，貝塔係數為 0.90。該公司的 50 日移動平均線為 14.23 美元，200 日移動平均線為 16.75 美元。</p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Syndax Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，開發用於癌症治療的療法。其主要產品候選藥物包括 revumenib，一種強效、選擇性的、針對 menin-MLL 結合相互作用的小分子抑制劑，用於治療 KMT2A 重排的急性白血病和實體腫瘤；以及 SNDX-6352 或 axatilimab，一種單克隆抗體，阻斷集落刺激因子 1（CSF-1）受體，用於治療慢性移植物抗宿主病（cGVHD）和特發性肺纖維化（IPF）患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Tesla Stock: Finding a Bottom May Take Time</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Duolingo: This Beaten-Down Stock Is About to Rally 38%</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Zoom Stock: Leading the Video Market After Skype’s Exit</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Syndax Pharmaceuticals</li>
<li>投資者需要了解的擊敗市場的信息</li>
<li>特斯拉股票：尋找底部可能需要時間</li>
<li>投資石油股票的方式和原因</li>
<li>Duolingo：這隻被打壓的股票即將反彈 38%</li>
<li>股息貴族的最佳名單：通過貴族指數積累財富</li>
<li>Zoom 股票：在 Skype 退出後引領視頻市場</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Syndax Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Syndax Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Syndax Pharmaceuticals 並不在名單上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Syndax Pharmaceuticals 目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Syndax 製藥（NASDAQ:SNDX）股價因令人失望的收益下跌 7.4%